Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Masimo Corporation is a global medical technology company specializing in noninvasive patient monitoring solutions. The company primarily operates in the medical devices and healthcare technology industries, with a core focus on technologies that improve patient outcomes and reduce the cost of care. Masimo is best known for its proprietary signal processing innovations used in pulse oximetry and advanced patient monitoring, which are deployed across hospitals, outpatient settings, and emergency medical environments.
Masimo’s primary revenue drivers include its Healthcare segment, which encompasses hospital monitoring platforms, sensors, and software, and, historically, a Consumer Audio segment following its acquisition of Sound United. The company serves hospitals, clinicians, and healthcare systems worldwide, with products often positioned as clinically superior alternatives to conventional monitoring technologies. Founded in 1989 by Joe Kiani, Masimo evolved from a startup focused on solving motion-related inaccuracies in pulse oximetry into a publicly traded company recognized for its strong intellectual property portfolio and recurring consumables-based revenue model.
Business Operations
Masimo generates revenue primarily through the sale of patient monitoring devices, proprietary disposable and reusable sensors, and associated software platforms under its Healthcare business. Core technologies include Masimo SET® pulse oximetry, rainbow® Pulse CO-Oximetry, noninvasive hemoglobin monitoring, brain function monitoring, and integrated patient surveillance systems such as Patient SafetyNet™. Revenue is driven by both capital equipment sales and high-margin consumables tied to ongoing clinical use.
The company operates globally with sales and distribution across North America, Europe, and Asia-Pacific, supported by a combination of direct sales forces and third-party distributors. Masimo controls key intellectual property related to signal extraction and owns manufacturing and R&D capabilities supporting continuous product development. The company has historically operated the Sound United consumer audio business as a subsidiary; however, Masimo announced a strategic divestiture of this business, and the transaction was in progress or recently completed based on public disclosures. Data inconclusive based on available public sources regarding the final post-transaction structure.
Strategic Position & Investments
Masimo’s strategy centers on expanding its installed base of hospital monitoring platforms while increasing recurring revenue through sensor utilization and software adoption. Growth initiatives include deeper integration of monitoring data into hospital IT systems, expansion of noninvasive parameters, and development of remote and automated patient surveillance technologies. The company continues to invest heavily in research and development to defend its technological differentiation.
Strategically, Masimo has pursued acquisitions to complement its core healthcare offerings, most notably the acquisition of Sound United to explore convergence between medical monitoring and consumer health technologies. Following shareholder and governance developments, Masimo announced plans to refocus on its core healthcare mission through divestiture of the consumer audio assets. The company maintains a portfolio of subsidiaries aligned primarily with medical monitoring and sensor technologies, while emerging efforts emphasize hospital automation, connectivity, and data-driven clinical decision support.
Geographic Footprint
Masimo is headquartered in Irvine, California, and maintains a significant operational presence across North America, Europe, and Asia-Pacific. The United States represents its largest single market, particularly for acute care hospital monitoring, while international markets contribute a substantial and growing portion of revenue through both developed and emerging healthcare systems.
The company operates sales offices, distribution hubs, and manufacturing or assembly facilities across multiple continents, enabling localized market access and regulatory compliance. Masimo’s technologies are used in hospitals and healthcare facilities in over 100 countries, reflecting a broad international footprint and diversified geographic revenue base.
Leadership & Governance
Masimo was founded by Joe Kiani, whose leadership has shaped the company’s long-term emphasis on clinical innovation, intellectual property protection, and patient safety. Governance and leadership are structured to support sustained investment in R&D while balancing profitability and shareholder interests.
Key executives include:
- Joe Kiani – Chairman of the Board and Chief Executive Officer
- Micah Young – Chief Financial Officer
- Mohammad Diab – Chief Technology Officer
Masimo’s leadership philosophy emphasizes innovation-driven growth, ethical clinical impact, and long-term value creation. The board and executive team have played a central role in recent strategic decisions, including portfolio realignment and capital allocation priorities.